This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
THOUSAND OAKS, Calif.,
May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix
®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin
®) plus FOLFOX as first-line treatment in patients with wild-type
RAS metastatic colorectal cancer (mCRC). The data was presented today at the 50
th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract No. 3629).
The data presented at ASCO was an extended analysis of the PEAK study that supports the use of panitumumab in combination with FOLFOX for patients with wild-type
RAS (absence of exons 2, 3, or 4
NRAS mutations) mCRC.
In this exploratory analysis, patients who received panitumumab plus FOLFOX and were then treated with a VEGF inhibitor-based treatment (including bevacizumab) had a median OS improvement of 41.3 months. By comparison, patients who received bevacizumab plus FOLFOX and were then treated with an anti-EGFR inhibitor-based treatment (including panitumumab/cetuximab), had a median OS improvement of 29.0 months. For both arms, outcomes were similar to those observed in the overall treated population with wild-type
"The initial PEAK data reinforce the potential importance of panitumumab for select patients, but we wanted to evaluate whether this benefit was dependent on administration with FOLFOX and if other subsequent treatments might impact survival outcomes," said
Fernando Rivera, M.D., Medical Oncology Department, Hospital Universitario Marques de Valdecilla, Santander,
Spain, and a lead investigator in the study. "These data suggest that a front-line treatment strategy with panitumumab in combination with FOLFOX may offer clinical benefit in patients with wild-type
RAS metastatic colorectal cancer compared to bevacizumab-based regimens in this treatment setting."
"The PEAK study not only shows the survival benefit of panitumumab in patients who have metastatic colorectal cancer with wild-type
KRAS tumors, but also gets us another step closer to understanding how unique genetic markers may change the way we treat cancers," said
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Every study we conduct as part of our comprehensive panitumumab development program adds to a growing understanding of how to personalize care for cancer patients."
Colorectal cancer is the third most common cancer in the U.S., and is the second leading cause of cancer deaths.
1,2 Approximately 1.2 million cases of colorectal cancer are expected to occur globally.
3About Vectibix ® (panitumumab) Vectibix is the first fully human anti-EGFR antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of mCRC. Vectibix was approved in the U.S. in
September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy.
May 2014, the FDA approved Vectibix
for use in combination with FOLFOX, as first-line treatment in patients with wild-type
KRAS (exon 2) mCRC. With this approval, Vectibix became the first and only biologic therapy indicated for use with FOLFOX, one of the most commonly used chemotherapy regimens, in the first-line treatment of mCRC for patients with wild-type
Important U.S. Product InformationVectibix is indicated for the treatment of patients with wild-type
KRAS (exon 2 in codons 12 or 13) mCRC as determined by an FDA-approved test for this use:
As first-line therapy in combination with FOLFOX
As monotherapy following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy
Vectibix is not indicated for the treatment of patients with
KRAS-mutant mCRC or for whom
KRAS mutation status is unknown.
WARNING: DERMATOLOGIC TOXICITY Dermatologic Toxicity: Dermatologic toxicities occurred in 90 percent of patients and were severe (NCI-CTC grade 3 or higher) in 15 percent of patients receiving Vectibix monotherapy. [See Dosage and Administration (2.1), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].
KRAS mutational status in colorectal tumors using an FDA-approved test indicated for this use is necessary for selection of patients for treatment with Vectibix. Patients with
KRAS-mutant mCRC tumors receiving Vectibix in combination with FOLFOX experienced shorter OS compared to FOLFOX alone.
Progressively decreasing serum magnesium levels leading to severe (Grade 3-4) hypomagnesemia occurred in up to 7% of patients across clinical trials. Monitor patients for hypomagnesemia and hypocalcemia prior to initiating Vectibix treatment, periodically during Vectibix treatment, and for up to 8 weeks after the completion of treatment.